본문 바로가기
KERD
논문KCI 등재

간신증후군

Hepatorenal Syndrome

이정표
대한내과학회 (The Korean Association Of Internal Medicine)|2016.05|대한내과학회지 (The Korean Journal of Medicine)|제90권 제5호|pp. 384-388

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

이식TransplantationRenal failureCirrhosis신부전Hepatorenal syndromeTerlipressin간경화간신증후군
주제분류내과학

초록

ㅍ신 기능 이상은 간경화 환자에서 중요한 문제이다. 이러한신 기능 이상은 복수 생성에 중요한 역할을 할 뿐 아니라, 간경화 환자들의 예후 인자로도 매우 중요하여 간 이식의 선별기준이 된다. 간신증후군(hepatorenal syndrome)은 순환 기능부전으로 인해 말기 간 질환에서 흔하게 발생하는 발생하는가역적인 신부전이다[1]. 간 질환의 합병증 중 가장 심한 것의 하나로 간주되며, 일반적으로 급성 간부전과 복수성 간경화 환자에서 발생한다. 병태 생리학적으로 간신증후군에서신장 기능 장애는 내인성 신장 질환이 없이 조직학적으로는정상이거나 아주 약간의 이상 소견만 관찰되며, 신장 피질의혈관 수축으로 인해 신장내 나트륨의 저류와 사구체 여과율의 감소, 핍뇨가 발생하는 것으로 이해되고 있다[2]. 일반적으로 대부분의 환자에서 이와 같은 형태의 신부전의 자연 경과는 치명적인 결과에 이르게 된다. 알부민과 바소프레신 유도체의 병합 치료, 간 이식에 의해 혈관 손상이 회복될 수있는 것으로 알려져 있다.

Abstract

Hepatorenal syndrome is a functional renal failure occurred in end-stage liver disease. It is regarded as one of the most serious complications of liver disease; commonly occur in patients with cirrhosis or acute liver failure. Pathophysiologically, portal hypertension induced vasoconstriction in the renal cortex reduces glomerular filtration rate. There are no intrinsic renal diseases or histological abnormalities. In most patients, the natural course of the renal failure leads to fatal consequences, even though various treatment options have been provided. Liver transplantation and combination therapy of albumin and vasopressin analogs can restore the damage of the blood vessel.

참고문헌 (27)

  1. Gines P, "Clinical disorders of renal function in cirrhosis with ascites" (1999), Blackwell Science
  2. Ginès P, "Hepatorenal syndrome", Lancet, 362, pp.1819~1827 (2003)
  3. Flint A, "Clinical Report on Hydro-Peritoneum, based on an analysis of forty-six cases", Am J Med Sci, 45, pp.306~339 (1863)
  4. Hecker R, "Electrolyte and circulatory changes in terminal liver failure", Lancet, 268, pp.1121~1125 (1956)
  5. Arroyo V, "Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club", Hepatology, 23, pp.164~176 (1996)
  6. Salerno F, "Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis", Gut, 56, pp.1310~1318 (2007)
  7. Alessandria C, "MELD score and clinical type predict prognosis in hepatorenal syndrome : relevance to liver transplantation", Hepatology, 41, pp.1282~1289 (2005)
  8. Ginès A, "Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites", Gastroenterology, 105, pp.229~236 (1993)
  9. Montoliu S, "Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites", Clin Gastroenterol Hepatol, 8, pp.616~622 (2010)
  10. Wadei HM, "Hepatorenal syndrome : pathophysiology and management", Clin J Am Soc Nephrol, 1, pp.1066~1079 (2006)
  11. Follo A, "Renal impairment after spontaneous bacterial peritonitis in cirrhosis : incidence, clinical course, predictive factors and prognosis", Hepatology, 20, pp.1495~1501 (1994)
  12. Wong F, "Sepsis in cirrhosis : report on the 7th meeting of the International Ascites Club", Gut, 54, pp.718~725 (2005)
  13. Ginès P, "Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis", Gastroenterology, 94, pp.1493~1502 (1988)
  14. Nadim MK, "Hepatorenal syndrome : the 8th International Consensus Conference of the Acute Dialysis Quality Initiative(ADQI)Group", Crit Care, 16, pp.23~ (2012)
  15. Moreau R, "The use of vasoconstrictors in patients with cirrhosis : type 1 HRS and beyond", Hepatology, 43, pp.385~394 (2006)
  16. Boyer TD, "Predictors of response to terlipressin plus albumin in hepatorenal syndrome(HRS)type 1 : relationship of serum creatinine to hemodynamics", J Hepatol, 55, pp.315~321 (2011)
  17. Nazar A, "Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome", Hepatology, 51, pp.219~226 (2010)
  18. Sanyal AJ, "A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome", Gastroenterology, 134, pp.1360~1368 (2008)
  19. Martín-Llahí M, "Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome : a randomized study", Gastroenterology, 134, pp.1352~1359 (2008)
  20. Brensing KA, "Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome : a phase II study", Gut, 47, pp.288~295 (2000)
  21. Testino G, "Type-2 hepatorenal syndrome and refractory ascites : role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation", Hepatogastroenterology, 50, pp.1753~1755 (2003)
  22. Guevara M, "Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome : effects on renal function and vasoactive systems", Hepatology, 28, pp.416~422 (1998)
  23. Mitzner SR, "Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS : results of a prospective, randomized, controlled clinical trial", Liver Transpl, 6, pp.277~286 (2000)
  24. Bañares R, "Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure : the RELIEF trial", Hepatology, 57, pp.1153~1162 (2013)
  25. Lee JP, "Clinical outcomes of patients with hepatorenal syndrome after living donor liver transplantation", Liver Transpl, 18, pp.1237~1244 (2012)
  26. Gonwa TA, "Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients", Transplantation, 51, pp.428~430 (1991)
  27. Gonwa TA, "Impact of pretransplant renal function on survival after liver transplantation", Transplantation, 59, pp.361~365 (1995)

관련 논문AI추천

Hepatorenal syndrome: Current concepts and future perspectivesChan-Young Jung, Jai Won Chang대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제4호간경변 환자의 관리이창형대한내과학회 · 대한내과학회지2012 · 제82권 제2호Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal고순영, 구자경, 권소영, 김정한, 양재훈, 이지영, 이창홍, 이초이, 최원혁, 최윤정대한간학회 · Clinical and Molecular Hepatology2014 · 제20권 제2호간경변성 복수 환자에서 Vaptan계열 약제의 유용성이준성, 최원혁대한내과학회 · 대한내과학회지2012 · 제82권 제1호간성뇌증김창욱대한내과학회 · 대한내과학회지2008 · 제75권 제1호Tracking the trajectory of kidney dysfunction in cirrhosis: the acute kidney injury: chronic kidney disease spectrumRakhi Maiwall, Vishnu Girish대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제3호

이 간행물의 다른 논문 (12건)

종양과 신장 질환이정은pp. 369-377심신증후군조상경pp. 378-383당뇨신병증의 최신 치료강영선pp. 402-405Colonic MALT Lymphoma Diagnosed 6 Months after Complete Remission of Gastric MALT Lymphoma송규상, 강선형, 정현용, 강성훈, 김석원, 문희석, 성재규pp. 416-420벌독 아나필락시스쇼크 후 병발한 신부전과스트레스성 심근병증 1예송용건, 조인수, 홍지연, 윤병우, 이창균, 이태연, 천미주pp. 427-432
원문 보기